Posts Tagged ‘phentermine/topiramate’
July 14, 2022 — We’ve all got our reading assignments. The Institute for Clinical and Economic Review (ICER) has released its draft report on effectiveness and value for the current options in obesity medicine. There’s a lot to process in there. But the bottom line is clear enough. Phentermine/topiramate (Qsymia) offers the best value, says the report. The most […]
January 24, 2015 — Let’s just say it. European regulators were spooked by obesity drugs for quite a few years. So news that first buproprion/naltrexone (Contrave U.S./Mysimba EU) and now liraglutide (Saxenda) have been recommended for approval in Europe is good news indeed. What spooked the Europeans was the experience with rimonobant. The European Commission (EC) granted Sanofi approval for this obesity treatment in 2006, […]
